NeuroTrauma Sciences, based in Alpharetta, GA, is a pioneering biopharmaceutical company focused on transforming the treatment of central nervous system (CNS) injuries. With a dedicated team of experts and a strong scientific foundation, the company is committed to developing innovative neuroprotective drugs to address conditions such as stroke and traumatic brain injury.
As a leader in the field, NeuroTrauma Sciences has commenced the first-in-human dosing of their investigational drug, NTS-104, in the United States. With a therapeutic focus on CNS injury, the company aims to revolutionize the way these conditions are treated, offering hope for improved outcomes and quality of life for patients.
Generated from the website